[HTML][HTML] Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau… - … England Journal of …, 2016 - Mass Medical Soc
Background The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau… - New England Journal …, 2016 - experts.umn.edu
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
Adaptive randomization of neratinib in early breast cancer
I-SPY 2 Investigators - New England Journal of …, 2016 - mayoclinic.elsevierpure.com
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
[引用][C] Adaptive Randomization of Neratinib in Early Breast Cancer
JW Park, MC Liu, D Yee, C Yau, LJ van't Veer… - New England Journal …, 2016 - cir.nii.ac.jp
Adaptive Randomization of Neratinib in Early Breast Cancer | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
Adaptive randomization of neratinib in early breast cancer
I-SPY 2 Investigators - New England …, 2016 - mdanderson.elsevierpure.com
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
Adaptive randomization of neratinib in early breast cancer
I-SPY 2 Investigators - New England …, 2016 - utsouthwestern.elsevierpure.com
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
Adaptive randomization of neratinib in early breast cancer
I-SPY 2 Investigators - New England Journal of …, 2016 - providence.elsevierpure.com
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
Adaptive Randomization of Neratinib in Early Breast Cancer.
JW Park, MC Liu, D Yee, C Yau… - The New England …, 2016 - europepmc.org
Background The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
[PDF][PDF] Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee - NOWOTWORY, 2016 - core.ac.uk
Metody. Do oceny standardowej indukcyjnej chemioterapii w połączeniu z inhibitorem
kinazy tyrozynowej neratynibem w porównaniu do grupy kontrolnej zastosowano …
kinazy tyrozynowej neratynibem w porównaniu do grupy kontrolnej zastosowano …
[PDF][PDF] Adaptive Randomization of Neratinib in Early Breast Cancer
JW Park, MC Liu, D Yee, C Yau, LJ van't Veer… - N Engl J Med, 2016 - academia.edu
BACKGROUND The heterogeneity of breast cancer makes identifying effective therapies
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …
challenging. The I-SPY 2 trial, a multicenter, adaptive phase 2 trial of neoadjuvant therapy …